Upload
joy-daugherty
View
28
Download
0
Tags:
Embed Size (px)
DESCRIPTION
ANTIAGREGANTS IN ACUTE CORONARY SYNDROME. Karlis TRUSINSKIS Interventional Cardiologist Pauls Stradins Clinical University Hospital Riga, LATVIA. Dual Antiplatelet Therapy. ASA + Clopidogrel I Class of evidence in treatment of ACS - PowerPoint PPT Presentation
Citation preview
Karlis TRUSINSKIS
Interventional Cardiologist
Pauls Stradins Clinical University Hospital
Riga, LATVIA
ANTIAGREGANTS
IN ACUTE CORONARY SYNDROME
Dual Antiplatelet Therapy
ASA + Clopidogrel
I Class of evidence in treatment of ACS
Beneficial, effective and useful in acute and long term treatment of ACS
Current standard in patients after stent implantation
Possible problems:
Increased risk of bleeding
Risk of stent thrombosis and MI in poor responders
Stent thrombosis of LAD bifurcation
Thrombosuction
Kissing balloon dilatation
Final Result
Days
Cu
mu
lati
ve H
azar
d
0.0
0.00
40.
008
0.01
2
0 3 6 9 12 15 18 21 24 27 30
Clopidogrel Standard Dose
Clopidogrel Double Dose
42% RRR
HR 0.5895% CI 0.42-0.79
P=0.001
Clopidogrel: Double (600mg and 150mg/d 1wk) vs Standard Dose (300mg) Definite Stent Thrombosis
Days
Cu
mu
lati
ve H
azar
d
0.0
0.01
0.02
0.03
0.04
0 3 6 9 12 15 18 21 24 27 30
Clopidogrel: Double vs Standard Dose Primary Outcome: PCI Patients
Clopidogrel Standard
Clopidogrel Double
HR 0.8595% CI 0.74-0.99
P=0.036
15% RRR15% RRR
CV Death, MI or StrokeCV Death, MI or Stroke
Clopidogrel Double vs Standard DoseBleeding PCI Population
Clopidogrel
Standard
N= 8684
Double
N=8548
Hazard
Ratio
95% CI P
TIMI Major1 0.5 0.5 1.06 0.70-1.61 0.79
CURRENT Major2 1.1 1.6 1.44 1.11-1.86 0.006
CURRENT Severe3 0.8 1.1 1.39 1.02-1.90 0.034
Fatal 0.15 0.07 0.47 0.18-1.23 0.125
ICH 0.035 0.046 1.35 0.30-6.04 0.69
RBC transfusion ≥ 2U 0.91 1.35 1.49 1.11-1.98 0.007
CABG-related Major 0.1 0.1 1.69 0.61-4.7 0.31
1ICH, Hb drop ≥ 5 g/dL (each unit of RBC transfusion counts as 1 g/dL drop) or fatal2Severe bleed + disabling or intraocular or requiring transfusion of 2-3 units3Fatal or ↓Hb ≥ 5 g/dL, sig hypotension + inotropes/surgery, ICH or txn of ≥ 4 units
1ICH, Hb drop ≥ 5 g/dL (each unit of RBC transfusion counts as 1 g/dL drop) or fatal2Severe bleed + disabling or intraocular or requiring transfusion of 2-3 units3Fatal or ↓Hb ≥ 5 g/dL, sig hypotension + inotropes/surgery, ICH or txn of ≥ 4 units
Conclusions
1.1. Double-dose clopidogrel significantly reduced stent Double-dose clopidogrel significantly reduced stent thrombosis and major CV events (CV death, MI or thrombosis and major CV events (CV death, MI or stroke) in PCI.stroke) in PCI.
2.2. In patients not undergoing PCI, double dose clopidogrel In patients not undergoing PCI, double dose clopidogrel was not significantly different from standard dose (70% was not significantly different from standard dose (70% had no significant CAD or stopped study drug early for had no significant CAD or stopped study drug early for CABG).CABG).
3.3. There was a modest excess in CURRENT-defined major There was a modest excess in CURRENT-defined major bleeds but no difference in TIMI major bleeds, ICH, fatal bleeds but no difference in TIMI major bleeds, ICH, fatal bleeds or CABG-related bleeds.bleeds or CABG-related bleeds.
4.4. No significant difference in efficacy or bleeding between No significant difference in efficacy or bleeding between ASA 300-325 mg and ASA 75-100 mgASA 300-325 mg and ASA 75-100 mg
Platelet Aggregation after Clopidogrel Loading
Hochholzer W et al, Circulation 2005
Survival free of cardiovascular death, infarction and stent thrombosis depending on platelet
reactivity
Price MJ et al. Eur heart J 2008
Inhibition of Platelet Aggregation
Double-blind
ACS (STEMI or UA/NSTEMI) & Planned PCI
ASA
PRASUGREL60 mg LD/ 10 mg MD
CLOPIDOGREL300 mg LD/ 75 mg MD
1o endpoint: CV death, MI, Stroke2o endpoint: Stent Thrombosis Safety endpoints: TIMI major bleeds, Life-threatening bleeds
Duration of therapy: 6-15 months
N= 13,608
Wiviott SD, Antman EM et al AHJ 2006
STENT ANALYSIS
0
5
10
15
0 30 60 90 180 270 360 450
HR 0.81(0.73-0.90)P=0.0004
Prasugrel
Clopidogrel
Days
En
dp
oin
t (%
)
12.1
9.9
HR 1.32(1.03-1.68)
P=0.03
Prasugrel
Clopidogrel1.82.4
Main Trial: Main Trial: Primary ResultsPrimary Results
CV Death / MI / Stroke
TIMI Major NonCABG Bleeds
Wiviott SD, Braunwald E, McCabe CH et al NEJM2007
Prasugrel in STEMI and UA/NSTEMI
Wiviott SD, Braunwald E, McCabe CH et al NEJM2007
Safety Profile of Prasugrel in STEMI vs UN/NSTEMI
Wiviott SD, Braunwald E, McCabe CH et al NEJM2007
Net Clinical Benefit in STEMI
Montalescot G et al. Lancet 2009
Diabetic SubgroupDiabetic Subgroup
0
2
4
6
8
10
12
14
16
18
0 30 60 90 180 270 360 450
HR 0.70P<0.001
Days
En
dp
oin
t (%
)
CV Death / MI / Stroke
TIMI Major NonCABG Bleeds
NNT = 21
N=3146N=3146
17.0
12.2
Prasugrel
Clopidogrel
Prasugrel
Clopidogrel 2.6
2.5
Wiviott et al NEJM 2007
Stent ThrombosisStent Thrombosis((Definite + Probable)Definite + Probable)
0
1
2
3
0 30 60 90 180 270 360 450
HR 0.48P <0.0001
Prasugrel
Clopidogrel2.4
(142)
NNT= 77
1.1 (68)
Days
En
dp
oin
t (%
)
Any Stent at Index PCIAny Stent at Index PCI N= 12,844 N= 12,844
Definite/Probable ST: Definite/Probable ST: Any Stent (N=12844)Any Stent (N=12844)
0
0.5
1
1.5
2
2.5
0 5 10 15 20 25 300
0.5
1
1.5
2
2.5
30 90 150 210 270 330 390 450
% o
f S
ubje
cts
HR 0.41 [0.29-0.59]P<0.0001
HR 0.60 [0.37-0.97]P=0.03
DAYS
EARLY ST LATE ST
STENT ANALYSIS
1.56%
0.64%
59% 0.82%
0.49%
40%
CLOPIDOGREL
PRASUGREL
Death Following STDeath Following ST
Mortality During Follow up (%) Post-Stent Thrombosis
STENT ANALYSIS
N=210 N=12634
HR 13.1 (9.8 – 17.5) P<0.0001
% o
f S
ubje
cts
Net Clinical BenefitNet Clinical BenefitBleeding Risk SubgroupsBleeding Risk Subgroups
OVERALL
>=60 kg
< 60 kg
< 75
>=75
No
Yes
0.5 1 2
Prior Stroke / TIA
Age
Wgt
Risk (%)
+ 54
-16
-1
-16
+3
-14
-13
Prasugrel Better Clopidogrel BetterHR
Pint = 0.006
Pint = 0.18
Pint = 0.36
Post-hoc analysisPost-hoc analysis
Wiviott et al NEJM 2007
• Thienopyridines act by binding covalently to the P2Y12 receptor, causing a structural change, and rendering the receptors
permanently inactivated
Irreversible inhibition - Thienopyridines
Reversible inhibition – Ticagrelor
P Savi, et al. Proc Natl Acad Sci USA 2006; 103:11069-11074.
ST
RIC
TLY
CO
NF
IDE
NT
TIA
L, F
OR
IN
TE
RN
AL
US
E O
NLY
.NO
T T
O B
E U
SE
D F
OR
SA
LES
PR
ES
EN
TA
TIO
NS
ST
RIC
TLY
CO
NF
IDE
NT
TIA
L, F
OR
IN
TE
RN
AL
US
E O
NLY
.NO
T T
O B
E U
SE
D F
OR
SA
LES
PR
ES
EN
TA
TIO
NS
0 2 4 6 8 10 120
20
40
60
80
**
*
*
**
*
**
**
*
Time postdose (h)
Mea
n P
late
let
Ag
gre
ga
tio
n
Clopidogrel 75 mg (n=12)
Ticagrelor 180 mg (n=7)
Ticagrelor 90 mg (n=9)
Ticagrelor 270 mg (n=16)
*P<0.05 for AZD6140 vs clopidogrel.Storey RF et al. J Am Coll Cardiol. 2007;50:1852-1856.
DISPERSE-2 PK/PD Substudy: Suppression of Platelet Aggregation in Clopidogrel-Pretreated Patients (N=44)
PLATO study design
Primary endpoint: CV death + MI + Stroke Primary safety endpint: Total major bleeding
6–12-month exposure
ClopidogrelIf pre-treated, no additional loading dose;if naive, standard 300 mg loading dose,
then 75 mg qd maintenance;(additional 300 mg allowed pre PCI)
Ticagrelor180 mg loading dose, then90 mg bid maintenance;
(additional 90 mg pre-PCI)
NSTE-ACS (moderate-to-high risk) STEMI (if primary PCI)Clopidogrel-treated or -naive;
randomised within 24 hours of index event (N=18,624)
PCI = percutaneous coronary intervention; ASA = acetylsalicylic acid; CV = cardiovascular; TIA = transient ischaemic attack
K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke)
No. at risk
Clopidogrel
Ticagrelor
9,291
9,333
8,521
8,628
8,362
8,460
8,124
Days after randomisation
6,743
6,743
5,096
5,161
4,047
4,147
0 60 120 180 240 300 360
1211109876543210
13
Cum
ula
tive inci
dence
(%
)
9.8
11.7
8,219
HR 0.84 (95% CI 0.77–0.92), p=0.0003
Clopidogrel
Ticagrelor
K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval
No. at risk
Clopidogrel
Ticagrelor
9,291
9,333
8,560
8,678
8,405
8,520
8,177
Days after randomisation
6,703
6,796
5,136
5,210
4,109
4,191
0 60 120 180 240 300 360
6
5
4
3
2
1
0
7
Cum
ula
tive in
cid
en
ce (
%)
Clopidogrel
Ticagrelor
5.8
6.9
8,279
HR 0.84 (95% CI 0.75–0.95), p=0.005
0 60 120 180 240 300 360
6
4
3
2
1
0
Clopidogrel
Ticagrelor
4.0
5.1
HR 0.79 (95% CI 0.69–0.91), p=0.001
7
5
9,291
9,333
8,865
8,294
8,780
8,822
8,589
Days after randomisation
7079
7119
5,441
5,482
4,364
4,4198,626
Myocardial infarction Cardiovascular death
Cum
ula
tive in
cid
en
ce (
%)
Secondary efficacy endpoints over time
Stent thrombosis
Ticagrelor
(n=5,640)
Clopidogre
l
(n=5,649)
HR
(95% CI)
p
value
Stent thrombosis, n (%)
Definite
Probable or definite
Possible, probable,
definite
71 (1.3)
118 (2.1)
155
(2.8)
106 (1.9)
158 (2.8)
202 (3.6)
0.67 (0.50–
0.91)
0.75 (0.59–
0.95)
0.77 (0.62–
0.95)
0.009
0.02
0.01
(evaluated in patients with any stent during the study)
*Time-at-risk is calculated from first stent insertion in the study or date of randomisation
Time to major bleeding – primary safety event
No. at risk
Clopidogrel
Ticagrelor
9,186
9,235
7,305
7,246
6,930
6,826
6,670
Days from first IP dose
5,209
5,129
3,841
3,783
3,479
3,433
0 60 120 180 240 300 360
10
5
0
15
Clopidogrel
Ticagrelor
11.2011.58
6,545
HR 1.04 (95% CI 0.95–1.13), p=0.434
K-M
est
imate
d r
ate
(%
per
year)
Holter monitoring & Bradycardia related events
Holter monitoring at first weekTicagrelor(n=1,451)
Clopidogrel(n=1,415) p value
Ventricular pauses ≥3
seconds, %
Ventricular pauses ≥5
seconds, %
5.8
2.0
3.6
1.2
0.01
0.10
Holter monitoring at 30 daysTicagrelor(n= 985)
Clopidogrel(n=1,006) p value
Ventricular pauses ≥3
seconds, %
Ventricular pauses ≥5
seconds, %
2.1
0.8
1.7
0.6
0.52
0.60
Bradycardia-related event, %
Ticagrelor(n=9,235)
Clopidogrel(n=9,186) p value
Pacemaker Insertion
Syncope
Bradycardia
Heart block
0.9
1.1
4.4
0.7
0.9
0.8
4.0
0.7
0.87
0.08
0.21
1.00
Other findings
All patientsTicagrelor(n=9,235)
Clopidogrel(n=9,186) p value*
Dyspnoea, %
Any
With discontinuation of study
treatment
13.8
0.9
7.8
0.1<0.001
<0.001
Neoplasms arising during treatment,
%
Any
Malignant
Benign
1.4
1.2
0.2
1.7
1.3
0.4
0.17
0.69
0.02
*p values were calculated using Fischer’s exact test
Conclusions
• Reversible, more intense P2Y12 receptor inhibition for one
year with ticagrelor in comparison with clopidogrel in a broad population with ST- and non-ST-elevation ACS provides
– Reduction in myocardial infarction and stent thrombosis
– Reduction in cardiovascular and total mortality
– No change in the overall risk of major bleeding
Funnel plots comparing prasugrel vs. ticagrelor for the risk of key Funnel plots comparing prasugrel vs. ticagrelor for the risk of key clinical events. Odds ratios (OR) <1.0 favor prasugrel, whereas odds clinical events. Odds ratios (OR) <1.0 favor prasugrel, whereas odds
ratios>1.0 favor ticagrelor.ratios>1.0 favor ticagrelor.
Indirect comparison Prasugrel vs. Ticagrelor
Zoccai GB. EuroPCR 2010
CYP2C19 Polymorphism and Response to Clopidogrel
Mega et al. N Engl J Med 2009;360:354-62.
CYP2C19 Polymorphism and Response to Prasugrel
Mega et al. Circulation. 2009;119:2553-2560
Cangrelor (AR-C69931MX)
Parenteral ADP-P2Y12 receptor antagonist
ATP analogue
Direct and Reversible P2Y12 inhibitor
More potent than clopidogrel ~90% inhibition of platelet
aggregation at 1 - 4 mcg/kg/min iv
Plasma half-life of 5-9 min.; 20 min. for return to normal platelet
function
O- O- O-
O-O OHO OH
P P PO O
N
HN
NN
N
N
S
S
CF3
O
Cl
Cl-O
CHAMPION Trial: Cangrelor versusStandard Therapy to Achieve Optimal Management
of Platelet Inhibition PCI
Harrington et al. N Engl J Med 2009;361:2318-29.
INNOVATE PCI: treatment with oral and intravenous Elinogrel
in setting of non-urgent PCI
• Second phase trial • Evaluation of clinical effectiveness, safety and
tolerability
Rao et al. ESC Congress 2010
Karlis TRUSINSKIS
Interventional Cardiologist
Pauls Stradins Clinical University Hospital
Riga, LATVIA
ANTIAGREGANTS
IN ACUTE CORONARY SYNDROME